Moderna announces first participant dosed in phase 2/3 study of its mrna respiratory syncytial virus (rsv) vaccine

Cambridge, mass.--(business wire)--moderna announces first participant dosed in phase 2/3 study of its mrna respiratory syncytial virus (rsv) vaccine

MRNA Ratings Summary

MRNA Quant Ranking